Imunon Statistics
Share Statistics
Imunon has 14.50M shares outstanding. The number of shares has increased by 102.87% in one year.
| Shares Outstanding | 14.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 53.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 13.79M |
| Failed to Deliver (FTD) Shares | 779 |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 485.69K, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 485.69K |
| Short % of Shares Out | 3.35% |
| Short % of Float | 3.52% |
| Short Ratio (days to cover) | 3.26 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is -0.71.
| PE Ratio | -0.32 |
| Forward PE | -0.71 |
| PS Ratio | 0 |
| Forward PS | 1.2 |
| PB Ratio | 0.46 |
| P/FCF Ratio | -0.32 |
| PEG Ratio | n/a |
Enterprise Valuation
Imunon Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.
| Current Ratio | 2.47 |
| Quick Ratio | 2.47 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.46% and return on capital (ROIC) is -131.46%.
| Return on Equity (ROE) | -1.46% |
| Return on Assets (ROA) | -0.89% |
| Return on Capital (ROIC) | -131.46% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -591.36K |
| Employee Count | 33 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.28M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -9.19% in the last 52 weeks. The beta is 2.13, so Imunon 's price volatility has been higher than the market average.
| Beta | 2.13 |
| 52-Week Price Change | -9.19% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 49.22 |
| Average Volume (20 Days) | 209.01K |
Income Statement
In the last 12 months, Imunon had revenue of $0 and earned -$19.51M in profits. Earnings per share was $-2.16.
| Revenue | 0 |
| Gross Profit | -720.00K |
| Operating Income | -21.03M |
| Net Income | -19.51M |
| EBITDA | -19.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.16 |
Balance Sheet
The company has $5.84M in cash and $1.62M in debt, giving a net cash position of $4.21M.
| Cash & Cash Equivalents | 5.84M |
| Total Debt | 1.62M |
| Net Cash | 4.21M |
| Retained Earnings | -388.18M |
| Total Assets | 14.39M |
| Working Capital | 7.09M |
Cash Flow
In the last 12 months, operating cash flow was -$19.02M and capital expenditures -$451.76K, giving a free cash flow of -$19.47M.
| Operating Cash Flow | -19.02M |
| Capital Expenditures | -451.76K |
| Free Cash Flow | -19.47M |
| FCF Per Share | -2.15 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
IMNN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -257.14% |
| FCF Yield | -159.02% |
Analyst Forecast
The average price target for IMNN is $29, which is 3352.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $29 |
| Price Target Difference | 3352.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 1, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Mar 1, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -41.66 |
| Piotroski F-Score | 2 |